Can-Fite Reports Additional Findings from Successful Phase II NASH Study: 25 mg Dose of Namodenoson Significantly Reduced Liver Fat and Fibrosis

Stock Information for Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Loading

Please wait while we load your information from QuoteMedia.